Loss of carcinoembryonic antigen-related cell adhesion molecule 1 expression is an adverse prognostic factor in hepatocellular carcinoma

Cancer

Volumn 104, Issue 2, 2005, Pages 354-360

  Cruz, Pauldion V ^a   Wakai, Toshifumi ^a   Shirai, Yoshio ^a   Yokoyama, Naoyuki ^a   Hatakeyama, Katsuyoshi ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Biliary glycoprotein; Carcinoembryonic antigen related cell adhesion molecule 1; Dedifferentiation; Hepatocellular carcinoma; Immunohistochemistry; Liver neoplasms; Multivariate analysis; Prognosis; Surgery

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INHIBITION; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; CELL ADHESION MOLECULES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 22244480610     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21159     Document Type: Article

References (41)

1. Thompson IA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal. 1991;5:344-366.
2. Beauchemin N, Draber P, Dveksler G, et al. Redefined nomenclature for members of the carcinoembryonic antigen family. Exp Cell Res. 1999;252:243-249.
3. Tanaka K, Hinoda Y, Takahashi H, Sakamoto H, Nakajima Y, Imai K. Decreased expression of biliary glycoprotein in hepatocellular carcinomas. Int J Cancer. 1997;74:15-19.
4. Borscheri N, Roessner A, Rocken C. Canalicular immunostaining of neprilysin (CD10) as a diagnostic marker for hepatocellular carcinomas. Am J Surg Pathol. 2001;25:1297-1303.
5. Hixson DC, Allison JP, Chesner JE, Leger MJ, Ridge LL, Walborg EF Jr. Characterization of a family of glycoproteins associated with the bile canalicular membrane of normal hepatocytes but not expressed by two transplantable rat hepatocellular carcinomas. Cancer Res. 1983;43:3874-3884.
6. Hixson DC, McEntire KD, Obrink B. Alterations in the expression of a hepatocyte cell adhesion molecule by transplantable rat hepatocellular carcinomas. Cancer Res. 1985;45:3742-3749.
7. Riethdorf L, Lisboa BW, Henkel U, Naumann M, Wagener C, Loning T. Differential expression of CD66a (BGP), a cell adhesion molecule of the carcinoembryonic antigen family, in benign, premalignant, and malignant lesions of the human mammary gland. J Histochem Cytochem. 1997;45:957-963.
8. Huang J, Simpson JF, Glackin C, Riethorf L, Wagener C, Shively JE. Expression of biliary glycoprotein (CD66a) in normal and malignant breast epithelial cells. Anticancer Res. 1998;18:3203-3212.
9. Neumaier M, Paululat S, Chan A, Matthaes P, Wagener C. Biliary glycoprotein, a potential human cell adhesion molecule, is down-regulated in colorectal carcinomas. Proc Natl Acad Sci USA. 1993;90:10744-10748.
10. Bamberger AM, Riethdorf L, Nollau P, et al. Dysregulated expression of CD66a (BGP, C-CAM), an adhesion molecule of the CEA family, in endometrial cancer. Am J Pathol. 1998;152:1401-1406.
11. Pu YS, Luo W, Lu HH, Greenberg NM, Lin SH. Differential expression of C-CAM cell adhesion molecule in prostate carcinogenesis in a transgenic mouse model. J. Urol. 1999;162:892-896.
12. Busch C, Hanssen TA, Wagener C, OBrink B. Down-regulation of CEACAM1 in human prostate cancer: correlation with loss of cell polarity, increased proliferation rate, and Gleason grade 3 to 4 transition. Hum Pathol. 2002;33:290-298.
13. Kleinerman DI, Troncoso P, Lin SH, et al. Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: implication as a tumor suppressor. Cancer Res. 1995;55:1215-1220.
14. Hsieh JT, Luo W, Song W, et al. Tumor suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches. Cancer Res. 1995;55:190-197.
15. Kleinerman DI, Zhang WW, Lin SH, Nguyen TV, von Eschenbach AC, Hsieh JT. Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: a preclinical study. Cancer Res. 1995;55:2831-2836.
16. Luo W, Wood CG, Earley K, Hung MC, Lin SH. Suppression of tumorigenicity of breast cancer cells by an epithelial cell adhesion molecule (C-CAM1): the adhesion and growth suppression are mediated by different domains. Oncogene. 1997;14:1697-1704.
17. Luo W, Tapolsky M, Earley K, et al. Tumor-suppressive activity of CD66a in prostate cancer. Cancer Gene Ther. 1999;6:313-321.
18. Plunkett TA, Ellis PA. CEACAM1: a marker with a difference or more of the same? J Clin Oncol. 2002;20:4273-4275.
19. Houde C, Roy S, Leung N, Nicholson DW, Beauchemin N. The cell adhesion molecule CEACAM1-L is a substrate of caspase-3-mediated cleavage in apoptotic mouse intestinal cells. J Biol Chem. 2003;278:16929-16935.
20. Laack E, Nikbakht H, Peters A, et al. Expression of CEACAM1 in adenocarcinoma of the lung: a factor of independent prognostic significance. J Clin Oncol. 2002;20:4279-4284.
21. Sienel W, Dango S, Woelfle U, et al. Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell lung cancer. Clin Cancer Res. 2003;9:2260-2266.
22. Thies A, Moll I, Berger J, et al. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol. 2002;20:2530-2536.
23. Kawasaki S, Sugiyama Y, Iga T, et al. Pharmacokinetic study on the hepatic uptake of indocyanine green in cirrhotic patients. Am J Gastroenterol. 1985;80:801-806.
24. Moody FG, Rikkers LF, Aldrete JS. Estimation of the functional reserve of human liver. Ann Surg. 1974;180:592-598.
25. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th edition. New York: Springer-Verlag, 2002.
26. Taylor M, Forster J, Langer B, Taylor BR, Greig PD, Mahut C. A study of prognostic factors for hepatic resection for colorectal metastases. Am J Surg. 1997;173:467-471.
27. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-699.
28. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462-503.
29. Wakai T, Shirai Y, Nomura T, Nagakura S, Hatakeyama K. Computed tomographic features of hepatocellular carcinoma predict long-term survival after hepatic resection. Eur J Surg Oncol. 2002;28:235-242.
30. Ergun S, Kilik N, Ziegeler G, et al. CEA-related cell adhesion molecule 1: a potent angiogenic factor and a major effector of vascular endothelial growth factor. Mol Cell 2000;5:311-320.
31. Volpert O, Luo W, Liu TJ, Estrera VT, Logothetis C, Lin SH. Inhibition of prostate tumor angiogenesis by the tumor suppressor CEACAM1. J Biol Chem. 2002;277:35696-35702.
32. Arakawa M, Kage M, Sugihara S, Nakashima T, Suenaga M, Okuda K. Emergence of malignant lesions within an adenomatous hyperplastic nodule in a cirrhotic liver. Observations in five cases. Gastroenterology. 1986;91:198-208.
33. Kenmochi K, Sugihara S, Kojiro M. Relationship of histologic grade of hepatocellular carcinoma (HCC) to tumor size, and demonstration of tumor cells of multiple different grades in single small HCC. Liver. 1987;7:18-26.
34. Sugihara S, Nakashima O, Kojiro M, Majima Y, Tanaka M, Tanikawa K. The morphologic transition in hepatocellular carcinoma. A comparison of the individual histologic features disclosed by ultrasound-guided fine-needle biopsy with those of autopsy. Cancer. 1992;70:1488-1492.
35. Uchida T. Small hepatocellular carcinoma: its relationship to multistep hepatocarcinogenesis. Pathol Int. 1995;45:175-184.
36. Hirohashi S, Ishak KG, Kojiro M, et al. Hepatocellular carcinoma. In: Hamilton SR, Aaltonen LA, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press, 2000:159-172.
37. Izumi R, Shimizu K, Ii T, et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology. 1994;106:720-727.
38. Vauthey JN, Klimstra D, Franceschi D, et al. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am J Surg. 1995;169:28-35.
39. Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol. 2002;20:1527-1536.
40. Wakai T, Shirai Y, Yokoyama N, Nagakura S, Hatakeyama K. Hepatitis viral status affects the pattern of intrahepatic recurrence after resection for hepatocellular carcinoma. Eur J Surg Oncol. 2003;29:266-271.
41. Yamanaka N, Okamoto E, Toyosaka A, et al. Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis. Cancer. 1990;65:1104-1110.